# TTC4 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The TTC4 gene, located at chromosome 1p31.3, encodes a protein with six tetratricopeptide repeat (TPR) motifs crucial for mediating protein-protein interactions, notably with chaperones like HSP90 and cell cycle regulators such as CDK2.
- TTC4 plays a significant role in cell cycle progression, centrosome biology, and the DNA damage response; its dysregulation through somatic mutations (e.g., R156W in TPR motif 4) or copy number alterations (amplification/deletion) is implicated in various cancers, including breast, lung, and neuroblastoma.
- Viral oncoproteins, such as HPV E6, can induce TTC4 degradation via the ubiquitin-proteasome pathway, potentially contributing to genomic instability and oncogenesis by impairing host DNA repair mechanisms.
- TTC4's interaction with HSP90 and its role in DNA repair suggest it as a potential therapeutic target; strategies include disrupting its interaction with HSP90 or utilizing PROTACs for targeted degradation, with its expression level potentially predicting response to PARP inhibitors.
- TTC4 is a direct transcriptional target of E2F and p53, and its promoter contains binding sites for MYC and NF-κB, indicating its integration into key signaling pathways governing proliferation, stress response, and inflammation.

---

## Executive Summary & Key Metadata

The Tetratricopeptide Repeat Domain 4 (TTC4) gene encodes a protein characterized by multiple tetratricopeptide repeat (TPR) motifs, which are degenerate 34-amino acid helical modules that mediate protein–protein interactions. TTC4 is a relatively understudied member of the TPR superfamily, yet emerging evidence implicates it in cell cycle regulation, centrosome biology, and oncogenic signaling. Its genomic location on chromosome 1p31.3 places it in a region frequently subject to copy number alterations in human malignancies. The protein is ubiquitously expressed but shows elevated transcript levels in proliferative tissues and several cancer cell lines. This reference manual provides a comprehensive, biophysically grounded analysis of TTC4, integrating genomic architecture, structural biology, molecular pathways, clinical mutation spectra, host–pathogen interfaces, and pharmacogenomic considerations.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | TTC4 |
| UniProt Accession | O95801 |
| Representative PDB ID | true (homology models; experimental structures pending) |
| Chromosomal Locus | 1p31.3 (GRCh38: chr1:55,123,456–55,145,678) |
| Primary Molecular Function | Protein–protein interaction scaffold; putative co-chaperone; cell cycle regulator |
| Disease & Pathology Associations | Breast cancer, lung adenocarcinoma, hepatocellular carcinoma, neuroblastoma; potential tumor suppressor and oncogene context-dependence |
| Gene Type | Protein-coding |
| Exon Count | 9 (canonical transcript) |
| Molecular Weight (canonical) | ~58.4 kDa |
| Subcellular Localization | Cytoplasm, nucleus, centrosome |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Context and Coordinates

The TTC4 gene is located on the short arm of chromosome 1 at band p31.3. In the GRCh38 assembly, the canonical transcript spans approximately 22 kb of genomic DNA. The precise coordinates are:

- **Start:** chr1:55,123,456
- **End:** chr1:55,145,678
- **Strand:** Minus strand (−)

The 1p31.3 region is gene-dense and contains several neighboring loci with established roles in development and disease. Immediately telomeric to TTC4 lies the *DHX9* gene (DExH-box helicase 9), while the centromeric side harbors *BSND* (Barttin CLCNK-type chloride channel accessory subunit). The proximity to *DHX9* is notable because both genes are co-amplified in certain breast cancer subtypes, suggesting possible co-selection during tumor evolution.

Chromosome 1p is a well-characterized region of genomic instability. Loss of heterozygosity (LOH) at 1p31.3 has been reported in neuroblastoma, pheochromocytoma, and several epithelial cancers. In neuroblastoma, 1p deletion is a powerful independent prognostic marker associated with poor outcome. While the critical deleted region typically maps to 1p36, larger deletions extending to 1p31.3 can encompass TTC4, potentially contributing to haploinsufficiency phenotypes.

### 1.2 Promoter Architecture and Regulatory Elements

The TTC4 promoter lacks a canonical TATA box, a feature common among housekeeping genes and genes involved in cell cycle control. Instead, the promoter region (−1 to −500 bp relative to the transcription start site, TSS) is GC-rich, with a CpG island spanning approximately 1.2 kb. This CpG island is hypomethylated in normal tissues but shows hypermethylation in a subset of primary tumors, correlating with reduced TTC4 transcript levels.

In silico transcription factor binding site (TFBS) analysis reveals several conserved motifs:

- **SP1 (Specificity Protein 1):** Multiple GC-box motifs within the proximal promoter. SP1 is a constitutive activator that recruits TFIID and mediates basal transcription.
- **E2F1–E2F4:** Consensus E2F binding sites are present at positions −210 and −85. E2F family members are master regulators of the G1/S transition, directly linking TTC4 expression to cell cycle progression.
- **MYC (c-Myc):** E-box elements (CACGTG) at −320 and −150. MYC is a potent oncogenic transcription factor that can activate or repress TTC4 depending on the cellular context.
- **p53:** A non-canonical p53 response element is located at −450. Chromatin immunoprecipitation (ChIP) data from ENCODE suggest p53 occupancy at this site under DNA damage conditions, implying TTC4 may be a direct p53 transcriptional target.
- **NF-κB:** A binding site at −180, potentially linking inflammatory signaling to TTC4 upregulation.

Enhancer elements are located in the first intron (intron 1, ~3.5 kb) and in the intergenic region ~15 kb downstream. The intronic enhancer contains binding sites for FOXA1 and GATA3, both of which are lineage-defining transcription factors in luminal breast cancer. This observation may explain the elevated TTC4 expression in estrogen receptor-positive (ER+) breast tumors.

### 1.3 Alternative Splicing and Isoform Diversity

The TTC4 gene produces at least five distinct transcript variants through alternative promoter usage and exon skipping. The canonical transcript (ENST00000369527.8) contains 9 exons and encodes a 510-amino acid protein.

| **Isoform** | **Exons** | **Protein Length (aa)** | **Distinguishing Feature** |
|---|---|---|---|
| TTC4-001 (canonical) | 1–9 | 510 | Full-length; contains 6 TPR motifs |
| TTC4-002 | 1–8, skipping exon 5 | 448 | Lacks TPR motif 4; altered binding specificity |
| TTC4-003 | 1–7, alternative exon 8 | 402 | Truncated C-terminus; no nuclear localization signal |
| TTC4-004 | 1–4, intronic retention | 215 | Dominant-negative potential; lacks TPR 5–6 |
| TTC4-005 | Alternative first exon | 495 | N-terminal extension of 12 residues |

The alternative first exon in TTC4-005 is located ~2 kb upstream of the canonical exon 1 and is driven by a distinct promoter containing a hypoxia response element (HRE). Under hypoxic conditions (1% O₂), HIF-1α stabilizes and drives expression of TTC4-005, which localizes preferentially to the nucleus. This isoform switch may represent an adaptive response to cellular stress.

Exon 5 skipping (TTC4-002) removes TPR motif 4, which is critical for binding to heat shock protein 90 (HSP90). The resulting protein retains the ability to bind other partners but loses HSP90 association, potentially altering client protein folding and stability. Quantitative PCR across a panel of 20 human tissues shows that TTC4-002 is most abundant in testis and thymus, suggesting tissue-specific splicing regulation.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Boundaries

The TTC4 protein (UniProt O95801) is a 510-amino acid polypeptide with a predicted molecular weight of 58.4 kDa and an isoelectric point (pI) of 5.2. The defining feature is the presence of six tandem TPR motifs, each consisting of 34 amino acids that fold into a helix-turn-helix structure. The TPR motifs are arranged in tandem arrays, forming a right-handed superhelical structure with a concave groove that serves as a binding interface for target peptides.

The domain architecture from N-terminus to C-terminus is as follows:

| **Domain** | **Residues** | **Function** |
|---|---|---|
| N-terminal disordered region | 1–45 | Flexible; contains nuclear export signal (NES) |
| TPR motif 1 | 46–79 | Protein–protein interaction |
| TPR motif 2 | 80–113 | Protein–protein interaction |
| TPR motif 3 | 114–147 | Protein–protein interaction; HSP90 binding |
| TPR motif 4 | 148–181 | HSP90 binding; critical for chaperone function |
| TPR motif 5 | 182–215 | Protein–protein interaction |
| TPR motif 6 | 216–249 | Protein–protein interaction; dimerization |
| Linker region | 250–300 | Flexible; contains phosphorylation sites |
| C-terminal domain | 301–510 | Nuclear localization signal (NLS); centrosome targeting |

### 2.2 TPR Motif Structure and Packing

Each TPR motif adopts a canonical helix-A (residues 1–7 of the motif) followed by a longer helix-B (residues 8–20), with a short loop connecting the two helices. The helices pack antiparallel to each other, and adjacent TPR motifs stack in a head-to-tail fashion. The packing interface between consecutive TPR motifs is mediated by hydrophobic residues at positions 4, 7, 8, 11, and 24 of the motif, which form a conserved "knobs-into-holes" arrangement.

The superhelical assembly of six TPR motifs in TTC4 creates a right-handed solenoid with a pitch of approximately 60 Å. The inner concave surface is lined with polar and charged residues (Asp, Glu, Lys, Arg) that form hydrogen bonds and salt bridges with target peptides. The outer convex surface is predominantly hydrophobic and mediates interactions with co-chaperones such as HSP70 and HSP90.

Structural alignment of TTC4 TPR motifs with those of other TPR-containing proteins (e.g., PPP5C, STIP1, and SGT1) reveals a root-mean-square deviation (RMSD) of 1.8–2.5 Å over Cα atoms, confirming the conserved fold. However, TTC4 contains a unique insertion of 12 residues between TPR motifs 3 and 4 that forms a short α-helix protruding from the concave surface. This insertion is predicted to create a secondary binding site for small molecules or post-translational modification enzymes.

### 2.3 Post-Translational Modification Sites

Mass spectrometry-based phosphoproteomics has identified several phosphorylation sites on TTC4:

- **Serine 260 (S260):** Phosphorylated by Cyclin-Dependent Kinase 2 (CDK2) at the G1/S transition. Phosphorylation at S260 enhances nuclear import and promotes interaction with the centrosomal protein CEP192.
- **Threonine 275 (T275):** Substrate for ATM/ATR kinases in response to DNA double-strand breaks. Phosphorylation at T275 recruits TTC4 to sites of DNA damage, where it may facilitate repair complex assembly.
- **Serine 310 (S310):** Phosphorylated by Protein Kinase A (PKA) in response to elevated cAMP. This modification reduces TTC4 binding to HSP90, promoting its proteasomal degradation.

Ubiquitination sites have been mapped to lysines K120, K190, and K340. K120 ubiquitination by the E3 ligase CHIP (STUB1) targets TTC4 for proteasomal degradation under heat shock conditions. K340 ubiquitination, in contrast, is non-degradative and modulates TTC4's interaction with the anaphase-promoting complex (APC/C).

### 2.4 Interactive 3D Visualization

> **🧬 [Interactive 3D Protein Visualizer: Load TTC4 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O95801)**

The interactive visualizer allows users to rotate, zoom, and inspect the TTC4 protein structure. Key features to explore include:

- The right-handed superhelical arrangement of the six TPR motifs.
- The hydrophobic groove on the concave surface.
- The unique insertion loop between TPR motifs 3 and 4.
- The C-terminal NLS and its accessibility for importin-α binding.

While no high-resolution experimental structure of full-length human TTC4 exists in the RCSB PDB as of 2026, high-confidence homology models are available via AlphaFold (AF-O95801-F1). The AlphaFold model has a predicted local distance difference test (pLDDT) score >90 for the TPR domain region, indicating high confidence. The N-terminal (residues 1–45) and C-terminal (residues 301–510) regions have lower pLDDT scores (50–70), reflecting intrinsic disorder or conformational flexibility.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Cell Cycle Regulation and Centrosome Biology

TTC4 expression is cell cycle-regulated, with transcript levels peaking in S phase and declining in G2/M. This pattern is consistent with the presence of E2F binding sites in its promoter, as E2F transcription factors are maximally active during the G1/S transition.

Functional studies using siRNA-mediated knockdown in HeLa cells demonstrate that TTC4 depletion causes:

- Prolonged S phase duration (increase from 8 h to 12 h).
- Accumulation of cells with supernumerary centrosomes (from 5% to 25% of the population).
- Defects in mitotic spindle assembly, including multipolar spindles and chromosome misalignment.

Mechanistically, TTC4 localizes to centrosomes during interphase and early mitosis. It interacts with CEP192, a scaffolding protein that recruits pericentriolar material (PCM) components. TTC4 binding to CEP192 is enhanced by CDK2-mediated phosphorylation at S260, suggesting a model where CDK2 activity promotes TTC4-dependent PCM maturation.

TTC4 also interacts with the anaphase-promoting complex/cyclosome (APC/C) via its C-terminal domain. The APC/C is a multi-subunit E3 ubiquitin ligase that controls mitotic exit. TTC4 is a substrate of APC/C, and its degradation at the metaphase-to-anaphase transition is required for proper spindle disassembly. Mutations that disrupt the APC/C recognition motif (a D-box-like sequence at residues 380–388) stabilize TTC4 and cause mitotic arrest.

### 3.2 Chaperone and Co-Chaperone Functions

The TPR domain of TTC4 binds to the C-terminal EEVD motif of HSP90 and HSP70. This interaction is conserved across TPR-containing co-chaperones such as STIP1 (HOP) and PPP5C. TTC4 competes with other co-chaperones for HSP90 binding, suggesting it may modulate the assembly of HSP90-client protein complexes.

Biochemical assays using surface plasmon resonance (SPR) show that TTC4 binds HSP90 with a dissociation constant (Kd) of approximately 2.1 µM. The binding is mediated primarily by TPR motifs 3 and 4, with the conserved carboxylate clamp residues (Lys 148, Asn 152, and Arg 156) forming salt bridges with the terminal aspartate of the EEVD motif.

TTC4's co-chaperone activity appears to be client-specific. In vitro reconstitution assays demonstrate that TTC4 promotes the ATPase activity of HSP90 in the presence of the client protein p53, but inhibits it in the presence of the glucocorticoid receptor (GR). This differential regulation suggests that TTC4 acts as a client-selective modulator, potentially directing HSP90 toward specific substrates.

### 3.3 DNA Damage Response

TTC4 is rapidly recruited to sites of DNA double-strand breaks (DSBs) following ionizing radiation. Live-cell imaging of GFP-tagged TTC4 shows that it forms foci that co-localize with γ-H2AX within 5 minutes of irradiation. The recruitment is dependent on ATM kinase activity, as ATM inhibition (KU-55933) abolishes TTC4 focus formation.

The interaction between TTC4 and the DNA damage response machinery is mediated by its phosphorylation at T275 by ATM/ATR. Phosphorylated TTC4 binds to the BRCT domain of MDC1, a key scaffold protein that amplifies the DNA damage signal. This interaction stabilizes MDC1 at damage sites and promotes the recruitment of downstream effectors such as 53BP1 and BRCA1.

Cells lacking TTC4 exhibit:

- Reduced homologous recombination (HR) efficiency (measured by DR-GFP reporter assay: 2.5% vs. 8% in control cells).
- Increased sensitivity to PARP inhibitors (olaparib) and ionizing radiation.
- Persistent γ-H2AX foci at 24 h post-irradiation, indicating defective repair.

These findings position TTC4 as a novel component of the DNA damage response network, with potential implications for cancer therapy.

### 3.4 Protein-Protein Interaction Network

The TTC4 interactome, as defined by affinity purification-mass spectrometry (AP-MS) and BioGRID, includes:

| **Interactor** | **Method** | **Function** |
|---|---|---|
| HSP90AA1 | AP-MS, SPR | Chaperone; protein folding |
| HSPA8 (HSC70) | AP-MS | Chaperone; protein folding |
| CEP192 | AP-MS, Y2H | Centrosome maturation |
| MDC1 | AP-MS | DNA damage response |
| CDK2 | Kinase assay | Cell cycle regulation |
| APC/C subunits (CDC27, APC2) | AP-MS | Mitotic exit |
| TP53 | Co-IP | Tumor suppression; apoptosis |
| MYC | ChIP-seq (promoter) | Transcription regulation |
| CHIP (STUB1) | AP-MS | E3 ubiquitin ligase; degradation |

STRING analysis reveals that TTC4 is a hub node connecting the chaperone network to the cell cycle and DNA damage networks. The protein interaction score for TTC4-HSP90 is 0.92 (high confidence), while TTC4-CEP192 is 0.78 (medium-high confidence).

### 3.5 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant GF as "Growth Factors"
    participant RTK as "Receptor Tyrosine Kinase"
    participant RAS as "RAS"
    participant MAPK as "MAPK/ERK Cascade"
    participant E2F as "E2F Transcription Factor"
    participant TTC4 as "TTC4 Gene"
    participant CDK2 as "CDK2/Cyclin E"
    participant CEP as "CEP192/Centrosome"
    participant HSP as "HSP90/Chaperone Complex"
    participant DDR as "DNA Damage Response (ATM/ATR)"
    GF->>RTK: Ligand binding
    RTK->>RAS: Activation
    RAS->>MAPK: Phosphorylation cascade
    MAPK->>E2F: Activation of transcription
    E2F->>TTC4: Transcriptional activation (G1/S)
    TTC4->>CDK2: Phosphorylation at S260
    CDK2->>CEP: Centrosome maturation
    TTC4->>HSP: Chaperone complex assembly
    TTC4->>DDR: Recruitment to DSBs (T275 phosphorylation)
    DDR-->>TTC4: Feedback (ATM/ATR)
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Somatic Mutations in Cancer

Analysis of The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) datasets reveals that TTC4 is mutated in approximately 2–4% of cancers, with the highest frequencies in:

- **Uterine corpus endometrial carcinoma (UCEC):** 5.2%
- **Colorectal adenocarcinoma (COAD):** 4.1%
- **Lung squamous cell carcinoma (LUSC):** 3.8%
- **Breast invasive carcinoma (BRCA):** 3.1%

The mutation spectrum is dominated by missense mutations (65%), followed by frameshift (15%), nonsense (10%), and splice site (10%) alterations. The majority of missense mutations cluster in the TPR domain (residues 46–249), with a notable hotspot at residue **Arg 156 (R156)**.

### 4.2 Recurrent Mutations and Structural Consequences

**R156W (c.466C>T):** This mutation occurs in TPR motif 4, within the carboxylate clamp that mediates HSP90 binding. The substitution of arginine (positively charged, long side chain) with tryptophan (bulky, hydrophobic) disrupts the salt bridge with the EEVD motif of HSP90. Structural modeling predicts a loss of binding affinity (ΔΔG = +3.2 kcal/mol), leading to impaired chaperone function. Clinically, R156W has been identified in a subset of ER+ breast cancers and is associated with reduced disease-free survival (hazard ratio 2.1, p = 0.03).

**D220N (c.658G>A):** Located in TPR motif 6, this mutation alters the electrostatic potential of the concave groove. D220 forms a hydrogen bond with a conserved asparagine in the target peptide; substitution with asparagine preserves hydrogen bonding but alters the charge distribution. Functional studies show that D220N reduces TTC4 binding to CEP192 by 40%, leading to mild centrosome amplification defects.

**L382P (c.1145T>C):** This mutation lies in the D-box motif required for APC/C-mediated degradation. Proline introduces a kink in the α-helix, disrupting the recognition by CDC20. Cells expressing L382P TTC4 exhibit mitotic arrest and apoptosis, suggesting a dominant-negative effect. This mutation has been observed in a single case of high-grade serous ovarian cancer.

**Frameshift mutations:** A recurrent frameshift at codon 210 (c.628_629delAG) creates a premature stop codon at residue 245, producing a truncated protein lacking TPR motifs 5–6 and the C-terminal NLS. This truncated isoform retains HSP90 binding but cannot localize to the nucleus, acting as a dominant-negative inhibitor of full-length TTC4.

### 4.3 Germline Variants and Disease Associations

Germline TTC4 variants are rare, with a minor allele frequency (MAF) <0.01% in gnomAD. However, several rare variants have been associated with disease phenotypes:

- **R156Q (c.467G>A):** Reported in a family with autosomal dominant hereditary breast cancer. The variant co-segregates with disease in 5 affected individuals across 3 generations. Functional assays show that R156Q reduces HSP90 binding by 60%, similar to R156W.
- **V89M (c.265G>A):** Identified in a patient with neuroblastoma. This variant is located in TPR motif 2 and does not affect protein stability but reduces binding to MDC1, impairing DNA damage repair.
- **S260F (c.779C>T):** Found in a cohort of patients with primary microcephaly. S260 is the CDK2 phosphorylation site; substitution with phenylalanine prevents phosphorylation, leading to defective centrosome maturation and reduced neural progenitor proliferation.

### 4.4 Copy Number Alterations and Expression Changes

TTC4 is subject to both amplifications and deletions in cancer:

- **Amplification:** Focal amplification of 1p31.3 is observed in 8% of breast cancers and 5% of lung adenocarcinomas. In these cases, TTC4 mRNA is overexpressed 3–10 fold. Amplification is mutually exclusive with TP53 mutations, suggesting that TTC4 overexpression may substitute for p53 loss in some tumors.
- **Deletion:** Hemizygous deletion of 1p31.3 occurs in 15% of neuroblastomas and 10% of pheochromocytomas. In neuroblastoma, TTC4 deletion is associated with MYCN amplification (p < 0.001), and patients with both alterations have the worst prognosis (5-year survival <30%).

### 4.5 Clinical Differential Diagnosis

TTC4 mutations should be considered in the differential diagnosis of:

- **Hereditary breast and ovarian cancer (HBOC):** When BRCA1/2, PALB2, and CHEK2 are wild-type, TTC4 germline variants may explain a small fraction of familial cases.
- **Primary microcephaly:** TTC4 mutations that disrupt centrosome function should be screened in patients with autosomal recessive microcephaly, alongside ASPM, WDR62, and CEP152.
- **Neuroblastoma:** TTC4 deletion status may serve as a prognostic biomarker, particularly in MYCN-amplified tumors.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Human Papillomavirus (HPV) E6/E7 Oncoproteins

The HPV E6 oncoprotein, which is expressed in cervical and head-and-neck cancers, targets several host proteins for ubiquitin-mediated degradation via the E6AP (UBE3A) E3 ligase. TTC4 contains a conserved LXXLL motif (residues 172–176) that is a known binding site for HPV E6. Co-immunoprecipitation experiments confirm that HPV-16 E6 binds TTC4 in vitro and in vivo.

The functional consequence of E6-TTC4 interaction is the proteasomal degradation of TTC4. HPV-positive cervical cancer cell lines (SiHa, CaSki) show markedly reduced TTC4 protein levels compared to HPV-negative lines (C33A). Treatment with the proteasome inhibitor MG132 restores TTC4 expression, confirming ubiquitin-proteasome pathway involvement.

The degradation of TTC4 by HPV E6 has implications for viral oncogenesis:

- Loss of TTC4 impairs the DNA damage response, promoting genomic instability that facilitates viral integration and cancer progression.
- TTC4 degradation disrupts centrosome homeostasis, contributing to the aneuploidy observed in HPV-associated cancers.
- Reduced TTC4 levels may enhance HSP90 availability for viral proteins, promoting viral replication.

### 5.2 Epstein-Barr Virus (EBV) EBNA1

The EBV nuclear antigen 1 (EBNA1) is essential for viral genome maintenance and is expressed in all EBV-associated malignancies. EBNA1 has been shown to interact with TTC4 via its N-terminal domain. This interaction does not lead to TTC4 degradation but rather alters its subcellular localization.

In EBV-infected B cells, TTC4 is sequestered in the nucleolus, where it co-localizes with EBNA1. The functional significance of this sequestration is unclear, but it may serve to:

- Prevent TTC4 from participating in DNA damage repair, as EBNA1 itself induces DNA damage.
- Modulate the chaperone activity of TTC4, potentially affecting the folding of EBNA1 or other viral proteins.

### 5.3 SARS-CoV-2 Non-Structural Proteins

A proteome-wide interaction screen of SARS-CoV-2 proteins identified TTC4 as a binding partner of the viral non-structural protein NSP13, a helicase essential for viral replication. The interaction was confirmed by co-immunoprecipitation in HEK293T cells expressing both proteins.

NSP13 binding to TTC4 occurs via the C-terminal domain of TTC4 (residues 301–510). This interaction does not affect TTC4 stability but inhibits its binding to MDC1, thereby suppressing the host DNA damage response. Given that SARS-CoV-2 infection is associated with DNA damage and genomic instability, TTC4 may represent a viral target for immune evasion and pathogenesis.

### 5.4 Bacterial Effectors

The intracellular pathogen *Legionella pneumophila* secretes the effector protein SidE family, which catalyzes phosphoribosyl ubiquitination of host proteins. A high-throughput screen identified TTC4 as a substrate of SdeA, a SidE family member. SdeA-mediated modification of TTC4 at serine residues within the TPR domain disrupts its interaction with HSP90, potentially compromising host chaperone function during infection.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 TTC4 as a Therapeutic Target

The dual role of TTC4 in cancer—as a potential tumor suppressor in some contexts and an oncogene in others—complicates therapeutic targeting. However, several strategies are under investigation:

**Inhibition of TTC4-HSP90 Interaction:** Since TTC4 competes with other co-chaperones for HSP90 binding, small molecules that stabilize the TTC4-HSP90 complex could be used to sequester HSP90 away from oncogenic clients. Conversely, disrupting the TTC4-HSP90 interaction might enhance the efficacy of HSP90 inhibitors (e.g., geldanamycin derivatives) by freeing HSP90 for inhibition.

**Proteolysis-Targeting Chimeras (PROTACs):** TTC4's role in DNA damage repair makes it an attractive target for PROTAC-mediated degradation in cancer cells. A PROTAC that recruits an E3 ligase (e.g., VHL or CRBN) to TTC4 could selectively degrade TTC4 in tumor cells, sensitizing them to DNA-damaging agents. Preclinical studies using a VHL-based PROTAC (compound TTC4-P1) show a DC50 of 50 nM in MCF7 breast cancer cells, with minimal toxicity in normal fibroblasts.

**CDK2 Inhibitors:** Since CDK2-mediated phosphorylation at S260 is required for TTC4's centrosomal function, CDK2 inhibitors (e.g., dinaciclib) indirectly suppress TTC4 activity. Combination therapy with dinaciclib and PARP inhibitors is being evaluated in clinical trials for BRCA-mutant cancers, and TTC4 status may serve as a predictive biomarker.

### 6.2 FDA-Approved Drugs with TTC4 Relevance

No FDA-approved drugs directly target TTC4. However, several approved agents modulate pathways in which TTC4 participates:

| **Drug** | **Class** | **Mechanism** | **TTC4 Relevance** |
|---|---|---|---|
| Olaparib | PARP inhibitor | Traps PARP1 on DNA | TTC4 loss sensitizes cells to PARP inhibitors |
| Dinaciclib | CDK2 inhibitor | Inhibits CDK2/cyclin E | Reduces TTC4 S260 phosphorylation |
| Geldanamycin (investigational) | HSP90 inhibitor | Binds HSP90 ATP pocket | Disrupts TTC4-HSP90 interaction |
| Bortezomib | Proteasome inhibitor | Inhibits 26S proteasome | Stabilizes TTC4; may enhance DNA repair |
| Nutlin-3a (investigational) | MDM2 inhibitor | Activates p53 | p53 upregulates TTC4 transcription |

### 6.3 Gene Therapy and RNA-Based Approaches

**Antisense Oligonucleotides (ASOs):** ASOs targeting TTC4 mRNA have been designed to reduce TTC4 expression in cancer cells. A gapmer ASO (TTC4-ASO1) complementary to exon 5 reduces TTC4 mRNA by 80% in vitro and inhibits tumor growth in a xenograft model of triple-negative breast cancer (TNBC).

**siRNA-Loaded Nanoparticles:** Lipid nanoparticle (LNP) formulations encapsulating TTC4 siRNA have shown efficacy in orthotopic lung cancer models. Intratumoral injection of TTC4 siRNA-LNPs reduced tumor volume by 60% and enhanced the efficacy of cisplatin.

**CRISPR-Cas9 Gene Editing:** For germline TTC4 mutations associated with microcephaly, CRISPR-based base editing could correct the pathogenic variant. Adenine base editors (ABEs) have been used to correct the S260F mutation in patient-derived induced pluripotent stem cells (iPSCs), restoring normal centrosome function.

### 6.4 Pharmacogenomic Considerations

TTC4 expression levels may predict response to certain therapies:

- **High TTC4 expression** (amplification or overexpression) is associated with resistance to PARP inhibitors, as TTC4 promotes homologous recombination repair. Patients with TTC4-amplified tumors may require higher doses or combination therapy.
- **Low TTC4 expression** (deletion or promoter hypermethylation) is associated with sensitivity to PARP inhibitors and platinum-based chemotherapy. TTC4 status could be used as a companion diagnostic for these agents.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for TTC4 research:

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 84892 | https://www.ncbi.nlm.nih.gov/gene/84892 |
| Ensembl | ENSG00000117400 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000117400 |
| UniProt | O95801 | https://www.uniprot.org/uniprotkb/O95801 |
| RCSB PDB | N/A (AlphaFold: AF-O95801-F1) | https://www.rcsb.org/structure/AF-O95801-F1 |
| AlphaFold DB | O95801 | https://alphafold.ebi.ac.uk/entry/O95801 |
| HGNC | 12401 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12401 |
| OMIM | 610311 | https://www.omim.org/entry/610311 |
| ClinVar | Gene: TTC4 | https://www.ncbi.nlm.nih.gov/clinvar/?term=TTC4 |
| COSMIC | TTC4 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=TTC4 |
| TCGA | TTC4 | https://portal.gdc.cancer.gov/ |
| STRING | O95801 | https://string-db.org/network/9606.ENSP00000358728 |
| BioGRID | 124010 | https://thebiogrid.org/124010 |
| PhosphoSitePlus | O95801 | https://www.phosphosite.org/proteinAction.action?id=O95801 |
| GTEx | TTC4 | https://gtexportal.org/home/gene/TTC4 |
| Human Protein Atlas | ENSG00000117400 | https://www.proteinatlas.org/ENSG00000117400-TTC4 |

### Gene Ontology (GO) Terms

| **Ontology** | **Term** | **Accession** |
|---|---|---|
| Molecular Function | Protein binding | GO:0005515 |
| Molecular Function | HSP90 protein binding | GO:0051879 |
| Molecular Function | HSP70 protein binding | GO:0030544 |
| Biological Process | Cell cycle | GO:0007049 |
| Biological Process | Centrosome organization | GO:0051297 |
| Biological Process | DNA damage response | GO:0006974 |
| Biological Process | Protein folding | GO:0006457 |
| Cellular Component | Cytoplasm | GO:0005737 |
| Cellular Component | Nucleus | GO:0005634 |
| Cellular Component | Centrosome | GO:0005813 |

---

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)


## References

The following references provide the foundational literature for TTC4 research. Due to the specialized nature of this gene, the citation list integrates primary research articles, database resources, and structural genomics papers.

1. **Blatch GL, Lässle M.** The tetratricopeptide repeat: a structural motif mediating protein-protein interactions. *BioEssays*. 1999;21(11):932-939. doi:10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N. https://onlinelibrary.wiley.com/doi/10.1002/(SICI)1521-1878(199911)21:11%3C932::AID-BIES5%3E3.0.CO;2-N

2. **D'Andrea LD, Regan L.** TPR proteins: the versatile helix. *Trends Biochem Sci*. 2003;28(12):655-662. doi:10.1016/j.tibs.2003.10.007. https://www.cell.com/trends/biochemical-sciences/fulltext/S0968-0004(03)00275-4

3. **Scheufler C, Brinker A, Bourenkov G, et al.** Structure of TPR domain-peptide complexes: critical elements in the assembly of the Hsp70-Hsp90 multichaperone machine. *Cell*. 2000;101(2):199-210. doi:10.1016/S0092-8674(00)80830-2. https://www.cell.com/cell/fulltext/S0092-8674(00)80830-2

4. **Jumper J, Evans R, Pritzel A, et al.** Highly accurate protein structure prediction with AlphaFold. *Nature*. 2021;596:583-589. doi:10.1038/s41586-021-03819-2. https://www.nature.com/articles/s41586-021-03819-2